BRPI0519570A2 - mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos - Google Patents

mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos

Info

Publication number
BRPI0519570A2
BRPI0519570A2 BRPI0519570-5A BRPI0519570A BRPI0519570A2 BR PI0519570 A2 BRPI0519570 A2 BR PI0519570A2 BR PI0519570 A BRPI0519570 A BR PI0519570A BR PI0519570 A2 BRPI0519570 A2 BR PI0519570A2
Authority
BR
Brazil
Prior art keywords
oligonucleotide
dose range
range determination
warfarin dose
warfarin
Prior art date
Application number
BRPI0519570-5A
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Hsiang-Yu Yuan
Jin-Jer Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0519570(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of BRPI0519570A2 publication Critical patent/BRPI0519570A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

MÉTODO DE DETERMINAÇçO DE FAIXA DE DOSE DE UMA WARFARINA PARA UM INDIVÍDUO, KIT PARA DETERMINAÇçO DA FAIXA DE DOSE DE UMA WARFARINA, OLIGONUCLEOTÍDEO OU COMPLEMENTO DO MESMO, E, ARRANJO DE OLIGONUCLEOTÍDEOS. Os requerentes verificaram que um polimorfismo no promotor do gene VKORC 1 é associado com a sensibilidade a warfarina. Este polimorfismo pode explicar tanto as diferenças inter-indivíduos como interétnicas em exigências de dose de warfarina. Além disso, o polimorfismo é também associado com a atividade do promotor. Assim, a seqúência ou atividade do promotor do gene VKORC 1 de um indivíduo pode ser usada para prover qual a quantidade de warfarina que deve ser receitada para o indivíduo. Métodos e composições relevantes são providos.
BRPI0519570-5A 2004-12-21 2005-12-21 mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos BRPI0519570A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63883704P 2004-12-21 2004-12-21
US67969405P 2005-05-10 2005-05-10
PCT/US2005/046869 WO2006069339A2 (en) 2004-12-21 2005-12-21 Genetic variants of vkorci predicting warfarin sensitivity

Publications (1)

Publication Number Publication Date
BRPI0519570A2 true BRPI0519570A2 (pt) 2009-01-27

Family

ID=36602356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519570-5A BRPI0519570A2 (pt) 2004-12-21 2005-12-21 mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos

Country Status (19)

Country Link
US (2) US20060166239A1 (pt)
EP (2) EP1831402B1 (pt)
JP (1) JP4516990B2 (pt)
KR (1) KR101178463B1 (pt)
CN (1) CN101142322B (pt)
AT (1) ATE470725T1 (pt)
AU (1) AU2005319028B2 (pt)
BR (1) BRPI0519570A2 (pt)
CA (1) CA2591840C (pt)
DE (1) DE602005021821D1 (pt)
DK (1) DK1831402T3 (pt)
ES (1) ES2347167T3 (pt)
HK (1) HK1117571A1 (pt)
MX (1) MX2007007568A (pt)
NZ (1) NZ556461A (pt)
PL (1) PL1831402T3 (pt)
PT (1) PT1831402E (pt)
TW (1) TWI334886B (pt)
WO (1) WO2006069339A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575903T3 (es) 2003-02-20 2016-07-04 Mayo Foundation For Medical Education And Research Métodos para seleccionar medicamentos antidepresivos
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
ES2339710T5 (es) * 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CA2911569C (en) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US8380539B2 (en) * 2006-05-09 2013-02-19 University Of Louisville Research Foundation, Inc. Personalized medicine management software
US8039212B2 (en) * 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
ES2927105T3 (es) * 2008-10-20 2022-11-02 Epitome Pharmaceuticals Ltd Métodos y sistemas para mejorar la intervención farmacéutica en el control de la coagulación
KR101157135B1 (ko) * 2008-12-29 2012-06-18 인제대학교 산학협력단 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법
EP2233580A1 (en) * 2009-03-05 2010-09-29 The Ohio State University Rapid genotyping of SNPs
JP5843487B2 (ja) * 2010-06-01 2016-01-13 アークレイ株式会社 Ｖｋｏｒｃ１遺伝子の−１６３９番目の塩基の多型検出法、ならびにそのための核酸プローブおよびキット
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
EP2708895B1 (en) * 2012-08-21 2019-05-08 Industrial Technology Research Institute Method for identifying more than one target nucleic acid contained in a sample
CN103173443B (zh) * 2013-03-22 2016-08-24 卫生部北京医院 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用
EP4119663A1 (en) 2016-12-09 2023-01-18 The Broad Institute, Inc. Crispr effector system based diagnostics
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
CN111742370A (zh) * 2017-05-12 2020-10-02 密歇根大学董事会 个体和队列药理学表型预测平台
AU2019213047A1 (en) 2018-01-29 2020-07-16 Massachusetts Institute Of Technology CRISPR effector system based diagnostics
WO2020186223A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Sherlock assays for tick-borne diseases
CN110592206A (zh) * 2019-09-11 2019-12-20 上海交通大学 一种利用rs9934438检测华法药效的试剂盒
KR102506347B1 (ko) 2021-05-11 2023-03-03 충북대학교 산학협력단 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
ES2339710T5 (es) * 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
EP1809767B1 (en) * 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
US20080005732A1 (en) * 2006-05-11 2008-01-03 Coon Robert F Method and System for Integrating Software Update Services with Software Applications

Also Published As

Publication number Publication date
JP4516990B2 (ja) 2010-08-04
WO2006069339A2 (en) 2006-06-29
PT1831402E (pt) 2010-09-10
AU2005319028B2 (en) 2010-09-16
PL1831402T3 (pl) 2010-12-31
HK1117571A1 (en) 2009-01-16
WO2006069339A3 (en) 2006-10-12
US20060166239A1 (en) 2006-07-27
TWI334886B (en) 2010-12-21
KR20080005179A (ko) 2008-01-10
EP1831402B1 (en) 2010-06-09
DE602005021821D1 (de) 2010-07-22
ATE470725T1 (de) 2010-06-15
MX2007007568A (es) 2008-03-11
CN101142322B (zh) 2011-09-21
NZ556461A (en) 2009-12-24
EP1831402A2 (en) 2007-09-12
WO2006069339A8 (en) 2010-06-03
CA2591840C (en) 2012-07-10
ES2347167T3 (es) 2010-10-26
CN101142322A (zh) 2008-03-12
JP2008523844A (ja) 2008-07-10
DK1831402T3 (da) 2010-09-20
US20110236885A1 (en) 2011-09-29
AU2005319028A1 (en) 2006-06-29
EP2246445A1 (en) 2010-11-03
CA2591840A1 (en) 2006-06-29
TW200637918A (en) 2006-11-01
KR101178463B1 (ko) 2012-09-07

Similar Documents

Publication Publication Date Title
BRPI0519570A2 (pt) mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos
WO2013074676A3 (en) Assays for selecting a treatment regimen for a subject with depression and methods for treatment
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
ATE438740T1 (de) Verfahren und nukleinsäuren zur analyse von mit der prognose von störungen der proliferation von prostatazellen assoziierter genexpression
EA201071319A1 (ru) Генетические маркеры контролирования массы и способы их применения
MX2007009809A (es) Amplificacion de sonda por seleccion.
BRPI0710054B8 (pt) métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
DK1842920T3 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
DE112005001317A5 (de) Polymorphismen im NOD2/Card15 Gen
BRPI0512745A (pt) métodos de genotipagem e de caracterizar um agente e kit
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
DK1776586T3 (da) Underlag til gennemförelse af funktionelle test af biologiske celler samt fremgangsmåde til coating af et underlag
WO2006089185A8 (en) Pharmacogenomic markers for prognosis of solid tumors
BRPI0604502A (pt) controles de ensino de metilação de gene
WO2005121366A8 (ja) 遺伝子マーカー及びその利用
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
DK1791973T3 (da) DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi
ATE488772T1 (de) Biomarker zur beurteilung der leberfunktion
DE602006018513D1 (de) Assoziation von pde4d-allelvarianten mit schlaganfall
AR043398A1 (es) Metodos de determinacion de un regimen quimioterapeutico basado en la perdida de heterocigosidad en el lugar de timidilato sintasa
EP1650300A4 (en) METHOD FOR ASSESSING THE RISK OF DRUG-INDUCED GRANULOCYTOPENIA

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]